PTC's ataluren flops in another PhIII and an analyst says it's clearly a dud; kill it
PTC Therapeutics has whiffed once again on Translarna (ataluren).
The biotech reported that ataluren, a repeat flop in Duchenne muscular dystrophy, failed a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
